Laura White, founder of Andon Bio and a member of Fitzsimons Innovation Community, has been selected for Activate’s 2026 fellowship cohort, joining 50 scientist-innovators working to translate scientific discoveries into commercially viable technologies. Andon Bio is developing a nanopore-based measurement platform designed to improve the predictability of protein production, an essential process in manufacturing biologic…
Jena Hausmann, president and CEO of Children’s Hospital Colorado and a member of the Fitzsimons Innovation Community Board of Directors, has been named to Becker’s Hospital Review’s 2026 list of 236 Women Hospital and Health System Presidents and CEOs to Know. The national recognition highlights Hausmann’s leadership of one of the country’s leading pediatric health…
HepQuant, a member of Fitzsimons Innovation Community, has received premarket approval from the U.S. Food and Drug Administration (FDA) for its SHUNT Liver Diagnostic Test, marking a significant regulatory milestone for the company’s liver disease diagnostic technology. The blood-based test measures liver function and helps clinicians identify certain patients with compensated cirrhosis who are unlikely…
GelSana Therapeutics, a member of Fitzsimons Innovation Community, has announced that two research collaborators, Babita Parajuli and Dr. Amy Wang, received the 2026 Robert B. Lindberg Basic Scientist Paper Award from the American Burn Association for research evaluating GelSana’s CleraFlex wound care technology. The award recognizes research demonstrating that CleraFlex significantly reduced bacterial burden and…
The Gates Institute at the University of Colorado Anschutz has received clearance from the U.S. Food and Drug Administration (FDA) to advance a novel CAR T-cell therapy into clinical testing for adults with relapsed or refractory acute myeloid leukemia. The milestone represents the first U.S. authorization for clinical testing of a CAR T-cell therapy targeting…
Fitzsimons Innovation Community President & CEO Kelly Brough was recently featured on Visit Aurora, Colorado’s The Gateway to the Rockies Podcast where she shared the bold vision behind the newly approved master plan and how the Fitzsimons campus is transforming into Aurora’s first true urban district. From cutting-edge research that’s reshaping patient care to green…
CU Anschutz researchers help lead the largest U.S. randomized trial highlighting ketamine’s cardiovascular risks while guiding emergency and critical care practice.
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.
A first-of-its-kind combination therapy could make treatment more effective by attacking hard-to-treat cancer from two angles.
The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced that 17 Colorado companies and eight researchers have been awarded Proof of Concept and Early-Stage Capital and Retention grants through OEDIT’s Advanced Industries Accelerator Program. Congratulations to the Fitzsimons Innovation Community Early-Stage Capital and Retention Grant Recipients: Onconaut…